Sangamo BioSciences | SGMO - Ordinary Share Capital


Sangamo BioSciences reported $1.77M in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.49M 108K Jun/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
Amgen USD 541M 0 Sep/2026
Bayer EUR 982.42M 0 Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Cipla INR 807.87M 88K Sep/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.72M 170K Jun/2026
CSL USD 482.13M 93.87M Dec/2025
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Grifols EUR 680.58M 846.11K Dec/2025
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.64M Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Merck USD 2.47B 1.05M Jun/2026
Novartis USD 1.89B 12.09M Sep/2026
Omeros USD 611K 17K Dec/2023
Pfizer USD 5.7B 0 Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Tectonic Therapeutic USD 19.24M 404.78K Jun/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026